The purpose of this research study is to evaluate the possible benefits of an investigational, but commercially available Galleri multi-cancer early detection (MCED) blood test which is designed to detect many types of cancer early in veterans who have served in the military in active duty.
The name of the screening blood test being studied is:
-GRAIL Galleri MCED test
Active-duty or National Guard/Reserves military service for four or more years
Age ≥ 45
Received care at a VA facility within past 5 years
Able to sign informed consent
Individuals diagnosed with invasive malignancy within 3 years of enrollment (non- melanoma skin cancer is acceptable)
Individuals with evidence of symptomatic or active cancer requiring therapeutic intervention at the time of participation (hormone therapy for breast/prostate cancer is acceptable)
Individuals in the process of being evaluated for a clinical suspicion of cancer
Dana-Farber Cancer Institute
Lead sponsor
United States Department of Defense
Collaborator